Her2

Related by string. HER2 * * HER2 positive breast cancer . HER2 positive . HER2 positivity . HER2 negative . HER2 positive metastatic breast . HER2 positive tumors . metastatic HER2 positive . metastatic HER2 negative . HER2 positive breast . HER2 overexpression . advanced HER2 positive . HER2 protein . HER2 + . HER2 gene . HER2 receptor . HER2 receptors . HER2 expression *

Related by context. All words. (Click for frequent words.) 66 HER2 66 eIF 4E 66 BRAF mutation 65 HER2 receptor 65 EGFR 64 FLT3 64 HER-2/neu 64 T#I [002] 64 HER2/neu 64 EGFR mutation 64 HER2 gene 63 KRAS mutation 63 estrogen receptor ER 63 epithelial tumors 63 BCR ABL 62 ErbB2 positive 62 WT1 62 K ras mutations 62 GPNMB 62 poly ADP ribose polymerase 62 PCa 62 estrogen receptor progesterone receptor 62 activating mutation 62 ERBB2 62 HER2 positive metastatic breast 62 ERCC1 62 MAGE A3 61 Clusterin 61 IGF 1R 61 EpCAM 61 autoantibody 61 survivin 61 androgen receptor AR 61 breast carcinoma 61 ovarian carcinoma 61 KRAS mutations 61 PARP inhibitor 61 EphB4 61 HER2 protein 60 PI3K Akt 60 EGFR inhibitors 60 EGFR receptor 60 EGFRvIII 60 Factor Receptor 60 receptor tyrosine kinase 60 factor receptor 60 E#F# 60 FGFR2 60 MUC1 60 AGTR1 60 FGFR1 60 hormone receptor positive 60 carcinoembryonic antigen 60 VEGF receptor 60 Epidermal Growth Factor Receptor 60 BRAF V#E 60 HER3 60 MDM2 60 c MET 60 mesothelin 60 hypermethylation 60 HER2 positive 60 hCG beta 60 Tumor Necrosis Factor 60 EGFr 60 uPAR 59 Estrogen Receptor 59 cytokeratin 59 K RAS 59 colorectal carcinoma 59 IGF IR 59 CIN2 + 59 CD# antibody [001] 59 BRAF V#E mutation 59 IL# [001] 59 activating mutations 59 HER2 receptors 59 gene amplification 59 CD4 + CD# 59 progesterone receptor 59 EZH2 59 BRAF mutations 59 GSTP1 59 VEGFR2 59 K ras 59 HER2 negative 59 cyclin D1 59 T#I mutation 59 oncoprotein 59 EGFR mutations 59 MAPK pathway 59 NKG2D 59 SPINK1 59 immunohistochemical staining 59 HER2 overexpression 59 PIK3CA 59 oncogenic 59 relapsed ovarian cancer 59 Aurora kinase 59 vimentin 59 Trastuzumab 58 imatinib Gleevec 58 independent prognostic marker 58 IL2 58 tyrosine kinase inhibitors 58 Akt activation 58 PDGFR 58 oncoproteins 58 KRAS oncogene 58 estrogen receptor 58 BRCA deficient 58 Enzastaurin 58 GLI1 58 breast carcinomas 58 cyclin E 58 antibody MT# 58 ErbB2 58 TNFa 58 Erlotinib 58 pDCs 58 proto oncogene 58 predictive biomarker 58 micrometastasis 58 EGFR protein 58 pertuzumab 58 EGFR gene 58 receptor tyrosine kinase inhibitor 58 antibody MAb 58 epithelial ovarian cancer 58 clusterin 58 c MYC 58 HER2 + 58 operable breast cancer 58 gefitinib Iressa 58 metastatic colorectal 58 EGF receptor 58 PARP inhibitors 58 Immunohistochemical analysis 58 activin 58 Hypoxia Inducible Factor 58 HDAC2 58 gastrointestinal stromal tumors GISTs 58 miR #a [002] 58 lobular carcinoma 58 ERalpha 58 nodal metastasis 58 CD#b 58 interleukin IL -# 58 pan HDAC inhibitor 58 ZNF# 58 beta subunit 58 immunostaining 58 B7 H4 58 irreversible inhibitor 58 HER1 58 autoantibodies 58 Flt3 58 MTHFR 58 myelofibrosis polycythemia vera 58 B7 H3 58 PAM4 58 TIMP 1 58 endometrial cancers 57 NSCLC tumors 57 erlotinib Tarceva ® 57 isoform 57 hormone refractory 57 TOP2A 57 metastatic malignant 57 Gleevec resistant 57 MMP9 57 castration resistant prostate cancer 57 Janus kinase 57 specific antigen 57 gastrointestinal stromal tumors GIST 57 Ki# 57 lymph node metastasis 57 distant metastasis 57 cisplatin resistant 57 binds selectively 57 gastrointestinal stromal tumors 57 hormone LHRH 57 LHRH receptor positive 57 EGFR mutant 57 JAK2 57 Foxp3 57 Caveolin 1 57 p# deficient 57 c myc 57 FGFR3 57 RASSF1A 57 prostate cancer CaP 57 ErbB 57 tumor antigen 57 EGFR pathway 57 CDK4 57 dimerization 57 prognostic marker 57 LKB1 57 lymph node metastases 57 beta1 integrin 57 MGMT gene 57 Upregulation 57 KRAS wild 57 generation antisense inhibitor 57 androgen independent 57 mutated KRAS gene 57 tyrosine kinase 57 surface glycoprotein 57 tyrosine kinase receptor 57 breast cancer subtypes 57 Her2/neu 57 somatostatin receptors 57 ON #.Na 57 M2 subunit 57 castrate resistant 57 carcinoembryonic antigen CEA 57 JAK2 V#F 57 IL #R 57 castrate resistant prostate cancer 57 PI3 kinase 57 PPARg 57 molecular abnormalities 57 EGFR TKI 57 Epratuzumab 57 CD# CD# 57 FGFR4 57 immunohistochemical 57 Herceptin trastuzumab 57 Vorinostat 57 KIT mutations 57 HER2 ErbB2 57 mitogen activated protein kinase 57 NSCLC 57 ER alpha 57 hTERT 57 cell adhesion molecule 57 HER2 neu 57 caveolin 1 57 LHRH receptor 57 chemoresistant 57 prognostic markers 57 prognostic factor 57 HAAH 57 precursor lesions 57 c KIT 57 VEGFR 57 Ceflatonin 57 prostate cancer AIPC 57 metastatic renal cell carcinoma 57 vWF 57 hormone receptor negative 57 MYCN 57 E selectin 57 LRP6 57 HDACi 57 prostate carcinoma 57 mCRC patients 57 KRAS 57 TNFalpha 57 p# MAPK 57 Phosphorylation 57 PPARgamma 57 mutated BRAF gene 57 adenocarcinomas 57 chemokine receptor 57 LDL receptor 57 epidermal growth 57 Neuvenge 57 mutational status 57 ERK1 2 57 breast tumors 57 KIF6 gene 57 HER2 amplification 57 malignant ascites 57 KRAS status 57 IMA# 57 grade cervical intraepithelial 57 breast cancers 57 mutated K ras 56 imatinib Gleevec ® 56 breast cancer metastasis 56 atypia 56 FGFR 56 TNFα 56 VEGFR1 56 dasatinib Sprycel ® 56 Pertuzumab 56 mRCC 56 HBsAg 56 factor receptor EGFR 56 Her-2/neu 56 TGF β 56 tumor suppressor protein 56 NQO1 56 TTR gene 56 P selectin 56 constitutively activated 56 miR #b [001] 56 progesterone receptor PR 56 Akt1 56 GRASPA ® 56 GISTs 56 plasmacytoid dendritic cells 56 Stat5 56 SGLT2 56 oncogene 56 F FDG PET 56 Zolinza 56 Akt 56 SNP rs# [001] 56 inhibit EGFR 56 Irinotecan 56 mRNA expression 56 CD# [002] 56 basal cell carcinoma BCC 56 luteinizing hormone releasing 56 TLR3 56 tumor subtypes 56 trastuzumab Herceptin 56 DNMT1 56 metabotropic glutamate receptors 56 renal carcinoma 56 UGT#A# 56 neuroblastoma tumors 56 metastatic cancers 56 malignant transformation 56 Rituximab 56 Oncogenic 56 AEG# 56 Rap1 56 tyrosine kinase inhibitor 56 tumors GIST 56 regulated kinase 56 protein tyrosine phosphatase 1B 56 TAp# 56 PDGF receptor 56 RANKL 56 Aromatase 56 goserelin 56 tumor specific antigen 56 diagnostic biomarker 56 HER2 expression 56 trans retinoic acid 56 Protein Kinase C 56 metastatic pancreatic 56 metastatic malignant melanoma 56 ABCB1 56 Pralatrexate 56 trabectedin 56 COX2 56 EGFR tyrosine kinase inhibitors 56 HCV protease 56 dasatinib Sprycel 56 metastatic lymph nodes 56 selective modulator 56 folate receptor 56 recurrent NSCLC 56 Lenalidomide 56 IL 1ß 56 promoter methylation 56 malignant pleural mesothelioma 56 NS5A 56 leukemia AML 56 CD# molecule 56 casein kinase 56 receptor molecule 56 Carcinoma 56 refractory metastatic 56 TNF α 56 IL 1β 56 hypoxia inducible factor 56 NF kB pathway 56 gemcitabine Gemzar 56 bone metastasis 56 PKCi 56 acid phosphatase PAP 56 phosphate S1P 56 azacytidine 56 alpha#beta# integrin 56 pCR 56 leukemic cell 56 Sorafenib 56 aurora kinase 56 premalignant lesions 56 p# mutation 56 chronic eosinophilic leukemia 56 CYP# [002] 56 medullary thyroid cancer 55 ixabepilone 55 angiogenesis inhibitor 55 tumorigenic 55 MAb 55 histone deacetylases 55 metastatic prostate 55 EGFR HER2 55 sarcomatoid 55 histologies 55 genomic alterations 55 RANK ligand 55 ABL1 55 MAP kinase 55 EphA2 55 syngeneic 55 serous ovarian cancer 55 urothelial carcinoma 55 Tie2 55 DFMO 55 Pharmacokinetics PK 55 p# mitogen activated 55 A3 adenosine receptor 55 HER2 HER2 55 HLA B# 55 HGPIN 55 seliciclib 55 HGS ETR1 55 hepatocellular cancer 55 Metastatic 55 PI3K inhibitor 55 IGFBP2 55 IFN gamma 55 Nedd4 55 progesterone receptors 55 progesterone receptor negative 55 pancreatic lung 55 IFN γ 55 mapatumumab 55 Syk 55 splice variants 55 mucinous 55 metastatic lesions 55 carcinomas 55 adrenoceptor 55 TrkA 55 B CLL 55 Interferon gamma 55 tumor vasculature 55 thyroglobulin 55 Bortezomib 55 STAT3 55 Pemetrexed 55 pT2 55 neuroendocrine cancers 55 tryptase 55 SOX9 55 antiangiogenic therapy 55 5alpha reductase 55 receptors EGFR 55 antisense oligonucleotide 55 SATB1 55 Dasatinib 55 Trp p8 55 CTLA 4 55 Her2 positive 55 AT1R 55 Src 55 HER2 positive tumors 55 peritoneal carcinomatosis 55 NPM1 mutation 55 somatic mutations 55 iNOS 55 Gefitinib 55 GATA3 55 IL 1beta 55 gastric adenocarcinoma 55 gastric cancers 55 colorectal carcinomas 55 specific antigen PSA 55 Bezielle 55 CD# antigen 55 Aflibercept 55 β catenin 55 NMIBC 55 gemcitabine carboplatin 55 situ LCIS 55 receptor blocker 55 CD# antibodies 55 whose tumors overexpress 55 trastuzumab 55 bevacizumab Avastin 55 small molecule inhibitors 55 TIMP 55 axillary lymph nodes 55 CagA 55 humanized antibody 55 co stimulatory molecules 55 estrogen receptor alpha 55 CEACAM1 55 heparanase 55 micrometastases 55 Malignant Melanoma 55 MSH2 55 Aurora Kinase 55 Aplidin 55 dasatinib 55 NFkB 55 Lymph node 55 RhoA 55 myeloproliferative diseases 55 prostate cancer CRPC 55 TCF#L# 55 Lyn kinase 55 Bcr Abl 55 antiproliferative effects 55 tNOX 55 phosphatidylinositol 3 55 thyroid hormone receptor 55 induces apoptosis 55 EGF receptors 55 histological subtype 55 Bleomycin 55 thyrotropin 55 cetuximab Erbitux 55 cell acute lymphoblastic 55 rheumatoid factor 55 hypermethylated 55 pro apoptotic 55 LNCaP cells 55 RRM1 55 CYT# potent vascular disrupting 55 galiximab 55 TGFBR1 * 6A 55 IGF1R 55 anti apoptotic proteins 55 hormone gastrin 55 taxane therapy 55 lymphoproliferative disorders 55 immunohistochemistry 55 cytostatic 55 V#F 55 estrogen receptor beta 55 Squamous 55 oral prodrug 55 interleukin IL 55 kinase inhibitors 55 trastuzumab Herceptin ® 55 HDACs 55 benign lesions 55 monocytes macrophages 55 MDR1 55 standard chemotherapy regimens 55 locoregional recurrence 55 NMP# 55 HSP# inhibitor 55 metaglidasen 55 OGG1 55 transactivation 55 kinase inhibition 55 TGF ß 55 nilotinib 55 PDGFR alpha 55 Papillary 55 BRAF mutant 55 prognostic biomarker 55 recurrent ovarian cancer 55 miRview mets 55 IFN α 55 ovarian cancers 55 colorectal cancer CRC 55 BCR ABL protein 55 decitabine 55 LRP5 54 cancer mCRC 54 ovarian tumors 54 completely resected 54 pulmonary metastases 54 isoenzyme 54 CCR1 54 hepatocellular carcinomas 54 nonsmall cell lung cancer 54 peptide antigens 54 MGd 54 #F FDG PET 54 hENT1 54 carcinoid 54 molecularly targeted 54 Kinase 54 Cdc7 54 HER2 positive breast cancer 54 Metastatic breast cancer 54 hedgehog pathway 54 c Src 54 kinase inhibitor 54 5FU 54 FDG-PET/CT 54 interferon IFN 54 alpha folate receptor 54 tumorigenesis 54 multiple myeloma MM 54 invasive ductal 54 extracellular domain 54 retinoic acid receptor 54 T2DM 54 costimulatory 54 anti EGFR antibody 54 SOD1 gene 54 Chemokine Receptor 54 LHRH 54 colon carcinoma 54 JAK2 enzyme 54 refractory prostate cancer 54 Cyclin E 54 BMP2 54 soluble receptor 54 FDG PET 54 BRAF gene 54 idiopathic myelofibrosis 54 neuroblastoma cells 54 GW# [003] 54 humanised antibody 54 Fludarabine 54 neoadjuvant chemotherapy 54 panitumumab Vectibix 54 IMC A# 54 CTLs 54 virulence genes 54 BRCA1 BRCA2 54 specific membrane antigen 54 XmAb# 54 Kinase Inhibitor 54 catenin 54 antitumor 54 CXCR4 54 upregulated 54 apoptotic 54 promoter hypermethylation 54 papillary RCC 54 Tyrosine Kinase 54 PC3 cells 54 HepG2 cells 54 alvespimycin 54 squamous cell lung cancer 54 thymidylate synthase TS 54 Adjuvant chemotherapy 54 FUS1 54 selectively inhibited 54 erlotinib Tarceva 54 pancreatic adenocarcinoma 54 Degarelix 54 Factor VEGF 54 shRNAs 54 glioma cells 54 invasive carcinoma 54 unresectable stage 54 enzastaurin 54 p#NTR 54 CTAP# Capsules 54 ß catenin 54 NKX#.# 54 aromatase 54 bladder ovarian 54 anti angiogenic agent 54 lung tumors 54 ALK inhibitors 54 miR #b [002] 54 Li Fraumeni 54 Immunohistochemical staining 54 mediated apoptosis 54 liver metastasis 54 metastases 54 tumors 54 humanized monoclonal antibody 54 endostatin 54 HPV# 54 DHFR 54 HER2 positive breast 54 atypical hyperplasia 54 MUC1 protein 54 selective inhibitors 54 T lymphocytes 54 precancer 54 situ CIS 54 HLA DR 54 N cadherin 54 tumor cells 54 CD# receptor 54 phosphorylate 54 endoglin 54 bcl 2 54 tumor suppressor gene 54 Tubulin 54 S#A# [002] 54 hydroxylase 54 S#P# 54 STRIDE PD 54 HRPC 54 bispecific antibody 54 Chronic Lymphocytic Leukemia 54 cMET 54 IgG1 monoclonal antibody 54 metastatic hormone refractory 54 CDH1 54 plasma kallikrein inhibitor 54 antiestrogen 54 ductal adenocarcinoma 54 Acute Myeloid Leukaemia AML 54 HDAC EGFR 54 IgG antibodies 54 NY ESO 54 E7 proteins 54 breast pancreatic 54 NS4A 54 myeloid cells 54 myeloma cells 54 splice variant 54 Fibroblast Growth Factor Receptor 54 tumor necrosis 54 MAPK 54 E cadherin 54 HIF 1alpha 54 Cervista HPV HR 54 antigen CD# 54 prostate adenocarcinoma 54 mRNA transcripts 54 cyclin dependent kinase inhibitor 54 selective agonist 54 glycogen synthase kinase 54 p# protein 54 Alkaline Phosphatase 54 liver metastases 54 Virulizin ® 54 aT cell 54 p# biomarker 54 MyVax R 54 IV NSCLC 54 Epirubicin 54 lung carcinomas 54 invasive lobular carcinoma 54 proteolytic cleavage 54 adrenergic receptors 54 fine needle aspiration 54 Adenomas 54 downregulated 54 trastuzumab DM1 54 Proxinium TM 54 selectively binds 54 HDAC6 54 MEK ERK 54 gene polymorphism 54 CD8 + 54 VE cadherin 54 PAK1 54 sarcosine 54 Adjuvant Chemotherapy 54 Temsirolimus 54 aberrantly activated 54 GRP# 54 chronic myeloid 54 MEK1 54 pancreatic carcinoma 54 immunohistochemistry IHC 54 IL #p# 54 transmembrane protein 54 inducible nitric oxide synthase 54 estrogen receptor negative 54 relapsed SCLC 54 orally administered inhibitor 54 Adjuvant Treatment 53 ^ sup #m 53 NS3 53 Fibroblast 53 olaparib 53 metastatic colorectal cancer 53 androgen receptors 53 BRCA mutations 53 cervical intraepithelial neoplasia 53 ASCUS 53 BRCA2 mutation carriers 53 anti CD3 53 homodimers 53 corticosteroid dexamethasone 53 TRAIL induced apoptosis 53 EOquin 53 EGFR expression 53 chemoresistance 53 metastatic prostate cancer 53 assessing T DM1 53 Myelofibrosis 53 SCCHN 53 nucleolin 53 inhibitory effects 53 PI3K 53 molecular subtypes 53 Exelixis XL# 53 endocrine therapies 53 B Cell Lymphoma 53 protein kinases 53 biliary tract cancer 53 LymphoStat B belimumab 53 prostate cancers 53 leukaemias 53 transfected cells 53 contralateral breast 53 paragangliomas 53 systemic lupus erythematosus SLE 53 KLF4 53 neoplasia 53 p# mutations 53 advanced adenomas 53 mutant KRAS 53 tumor suppressor genes 53 intratumoral injection 53 thymalfasin 53 ERa 53 HIF 1α 53 EGFR HER 53 ApoB 53 hCG Beta 53 Cell Lymphoma 53 EUS FNA 53 malignant ovarian 53 BCG refractory 53 cyclins 53 imatinib therapy 53 chemotherapeutic agents 53 Liposomal 53 Survivin 53 cervical breast 53 prostate specific 53 melatonin receptor 53 alkylating agents 53 ductal cancer 53 ZACTIMA 53 LTB4 53 PKC delta 53 Notch1 53 Pegylated Interferon 53 tissue transglutaminase 53 prostate cancer PCa 53 adhesion molecule 53 estrogen receptor positive 53 CanAg 53 pT3 53 prostate cancer antigen prostatic 53 phosphorylates 53 differentiated thyroid 53 beta catenin 53 pancreatic cancers 53 malignant lesions 53 pelvic lymphadenectomy 53 Heterozygous 53 advanced hepatocellular carcinoma 53 MET amplification 53 phosphoprotein 53 interferon γ 53 ras gene 53 metastatic renal cell 53 Th# 53 p#Kip# 53 YONDELIS 53 phospho 53 lysyl oxidase 53 Th1 53 Bevacizumab 53 clonogenic 53 proteasome inhibitors 53 bladder cancers 53 elacytarabine 53 platinum refractory 53 K ras gene 53 CYC# 53 BRCA1 53 gene rearrangements 53 kinase 53 serine protease 53 NFκB 53 JAK3 53 ubiquitination 53 tumor suppressor 53 cyclooxygenase 53 lymphomas 53 pegylated liposomal doxorubicin 53 clinicopathological features 53 flavopiridol 53 tumorigenicity 53 PCA3 53 Smad3 53 HER2 antibody 53 constitutively active 53 mutated p# 53 CDK inhibitor 53 metastatic 53 PGE2 53 Annamycin 53 Fludara ® 53 FOLFOX6 53 proapoptotic 53 Smoothened 53 CCR9 53 abnormal cytology 53 53 mycosis fungoides 53 inhibit replication 53 thymidine kinase 53 neoadjuvant 53 chimeric monoclonal antibody 53 Wnt beta catenin 53 cervical carcinoma 53 53 E cadherin expression 53 antitumor activity 53 IFN g 53 GBM tumors 53 benign moles 53 Imatinib 53 PARP inhibition 53 CCR2 53 PTEN mutations 53 NPC 1C 53 urothelial bladder cancer 53 depsipeptide 53 fluoropyrimidine 53 thyroid peroxidase 53 RAR beta 53 chronic lymphocytic leukemia CLL 53 glioblastoma cells 53 anaplastic lymphoma kinase 53 phosphatase 53 CBLC# 53 thrombin receptor 53 prostate abnormalities 53 bleomycin 53 CD#c 53 overexpress HER2 53 malignant cells 53 neoplastic 53 pelvic malignancies 53 Cloretazine 53 macrophage colony stimulating 53 prostate pancreatic 53 IRAK1 53 K#R [002] 53 Apaziquone 53 p#INK#a 53 refractory chronic lymphocytic 53 nonalcoholic steatohepatitis NASH 53 5 HT2A serotonin 53 Vandetanib 53 chemopreventive agent 53 Amrubicin 53 gastrointestinal stromal tumor GIST 53 inhibin 53 Interferon Alfa 53 cytolytic 53 antiapoptotic 53 Hodgkin lymphoma NHL 53 BCL2 53 Vidofludimus 53 pyruvate kinase 53 ADAMTS# 53 potently inhibited 53 cyclooxygenase 2 53 hA# 53 adjuvant chemotherapy 53 BRAF protein 53 CD# protein 53 Antitumor Activity 53 epithelial cancers 53 colony stimulating factor 53 prognostic indicator 53 Overexpression 53 sunitinib Sutent 53 imatinib resistance 53 xenograft models 53 Raf MEK ERK 53 induce apoptosis 53 cathepsins 53 cetuximab Erbitux R 53 papillary thyroid carcinoma 53 ENaC 53 calcium calmodulin dependent 53 leukocyte adhesion 53 IV melanoma 53 #F FDG 53 antisense oligonucleotides 53 cathepsin B 53 DNA hypermethylation 53 eNOS 53 prostate ovarian 53 Secretase 53 ERK pathway 53 Hormone Refractory Prostate Cancer 53 metastatic carcinoma 53 deletion 5q 53 GSTT1 53 TNF Blockers 53 taxane chemotherapy 53 ELACYT 53 hormone refractory prostate cancer 53 hepatocellular carcinoma HCC 53 Recurrence Score 53 biliary cancer 53 delta isoform 53 hypereosinophilic syndrome 53 AhR 53 Panzem R NCD 53 Antitumor 53 serotonin receptor 53 FasL

Back to home page